{
    "clinical_study": {
        "@rank": "8370", 
        "acronym": "oxytocin", 
        "arm_group": [
            {
                "arm_group_label": "intravenous 10 \u0131u oxytocin", 
                "arm_group_type": "Active Comparator", 
                "description": "group which 2 ampul prophylactic oxytocin given for third stage of labour intravenously after vaginal delivery"
            }, 
            {
                "arm_group_label": "intramusculer 10 \u0131u oxytocin", 
                "arm_group_type": "Experimental", 
                "description": "group which oxytocin administered intramusculary after vaginal delivery"
            }
        ], 
        "brief_summary": {
            "textblock": "Intramuscular versus intravenous prophylactic oxytocin for the third stage of labour\n      following vaginal delivery: A randomised controlled trial"
        }, 
        "brief_title": "Intramuscular Versus Intravenous Prophylactic Oxytocin for Hemorrhage After Vaginal Delivery", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Postpartum Hemorrhage", 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Postpartum Hemorrhage"
            ]
        }, 
        "detailed_description": {
            "textblock": "Prevention of postpartum haemorrhage is essential in the pursuit of improved health care for\n      women. In this study investigators  aimed to compare intramuscular oxytocin with intravenous\n      oxytocin for the routine prevention of postpartum haemorrhage in women who deliver\n      vaginally.In some countries, intravenous access can not be provided easily . Intramuscular\n      application is faster , easier and tougher enforcement requires less skill and equipment .\n      For this reason, less educated , which can be applied by those offering health services ."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Research volunteers, the undersigned, pregnant women\n\n          2. Only with vaginal delivery (episiotomy and perineal tears can)\n\n          3. > 34 weeks or more will be\n\n          4. Cephalic presentation will be\n\n          5. At low risk of postpartum hemorrhage\n\n        Exclusion Criteria:\n\n          1. <18 years\n\n          2. Multiple pregnancies\n\n          3. The presence of uterine myoma\n\n          4. Having postpartum hemorrhage in previous pregnancies\n\n          5. Placenta previa, polyhydramnios\n\n          6. More than four parity\n\n          7. Fetal macrosomia\n\n          8. Hb <9mg/dl\n\n          9. preeclampsia\n\n         10. Uterine anomalies\n\n         11. Receiving anticoagulant therapy, suspected coagulopathy\n\n         12. > 42 weeks of pregnancy\n\n         13. Oxytocin allergy -"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02080104", 
            "org_study_id": "27-01.14-02-02"
        }, 
        "intervention": {
            "arm_group_label": [
                "intravenous 10 \u0131u oxytocin", 
                "intramusculer 10 \u0131u oxytocin"
            ], 
            "description": "intarvenous and intramusculer 10 IU oxytocin", 
            "intervention_name": "intarvenous and intramusculer 10 IU oxytocin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Oxytocin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "postpartum hemorrhage", 
            "oxytocin", 
            "vaginal delivery", 
            "prophylactic"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "contact": {
                "email": "hediyedagdeviren@gmail.com", 
                "last_name": "hediye da\u011fdeviren , md", 
                "phone": "2124147171", 
                "phone_ext": "7372"
            }, 
            "facility": {
                "address": {
                    "city": "Istanbul", 
                    "country": "Turkey", 
                    "zip": "34140"
                }, 
                "name": "Bak\u0131rkoy Dr Sadi Konuk Teaching and Research Hospital"
            }, 
            "investigator": {
                "last_name": "h\u00fcseyin cengiz, md", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_arms": "2", 
        "official_title": "Intramuscular Versus Intravenous Prophylactic Oxytocin for the Third Stage of Labour Following Vaginal Delivery: A Randomised Controlled Trial", 
        "overall_contact": {
            "email": "nurten.aydemir@beah.gov.tr", 
            "last_name": "nurten kayacan aydemir", 
            "phone": "2124147171", 
            "phone_ext": "7372"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Turkey: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Blood loss during the birth and postpartum hemorrhage asset (within 24 hours> 500 cc blood loss)", 
            "measure": "early postpartum hemorrhage", 
            "safety_issue": "No", 
            "time_frame": "postpartum 24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02080104"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Bakirkoy Dr. Sadi Konuk Research and Training Hospital", 
            "investigator_full_name": "Hediye Dagdeviren", 
            "investigator_title": "md", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "Blood transfusion requirement\nduration of phase 3 (> 30 min)\nnecessity of  additional treatments for postpartum hemorrhage\nthe necessity of manual removal of placenta\nside effects of the", 
            "measure": "Blood transfusion requirement", 
            "safety_issue": "No", 
            "time_frame": "postpartum 24 hours"
        }, 
        "source": "Bakirkoy Dr. Sadi Konuk Research and Training Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hediye Dagdeviren", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}